Resumo

ROSSELLI, Diego et al. Cost-effectiveness of statins for the treatment of dyslipidemia in Colombia. Acta Med Colomb [online]. 2015, vol.40, n.2, pp.118-124. ISSN 0120-2448.

Objective: to determine the relative cost-effectiveness among statins in adult patients with dyslipidemia with predominant hypercholesterolemia to prevent cardiocerebrovascular events in Colombia, from the perspective of Colombian health system. Methods: a Markov model with quality-adjusted life years (QALY) gained as the main outcome, discount rate of 3% for both costs and outcomes, and five-year time horizon was built. Probabilities and costs were extracted from the literature and from official sources in the country, respectively. The threshold for cost-effectiveness was three times the 2012 per capita GDP. Univariate probabilistic, sensitivity analysis, threshold and acceptability curve were performed. Results: the average cost of statin therapy for a patient with dyslipidemia in five years is $3 472 733. The QALY gain was higher in rosuvastatin compared to other statins, however, it is the most costly strategy. Atorvastatin, which was second, is the most cost-effective. Conclusion: the most cost-effective intervention for patients with dyslipidemia with predominant hypercholesterolemia and indication of pharmacological management with moderate and high statin therapy in Colombia is atorvastatin. (Acta Med Colomb 2015; 40: 118-124).

Palavras-chave : cost-effectiveness analysis; statins; dyslipidemia; Colombia; economic analysis.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )